The final entry deadline for the International Clinical
Researcher of the Year 2017 competition has now passed, and the finalists have been invited to compete at the rigorous Final Day. Who will be awarded the coveted Pharma in front of an audience of their industry peers?
Mundipharma is gearing up to launch biosimilar Truxima in seven European markets for the treatment of certain cancers and inflammatory conditions, after Celltrion bagged a regulatory approval for the drug.
US regulators have agreed to undertake a speedy review of Pfizer's experimental drug inotuzumab ozogamicin as a treatment for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Merck Sharp & Dohme (MSD) and Wayra UK have unveiled the 2017 winners of Velocity Health, a ground-breaking preventative digital healthcare accelerator programme designed to address key care challenges.
The National Institute for Health and Care Excellence has issued its first draft guidelines on Ipsen's Cabometyx, recommending against the drug's routine use on the National Health Service as a treatment for pre-treated advanced renal cell carcinoma.